問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

侯雅元

Recruiting

List

5Cases

2024-03-01 - 2027-11-10

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-08-01 - 2027-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2025-02-01 - 2027-12-31

Phase II

Completed
A Phase 2, Randomized, Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults with Generalized Myasthenia Gravis (MAGIC)

  • Condition/Disease

    Myasthenia Gravis, Generalized

  • Test Drug

    DNTH103

Participate Sites
8Sites

Recruiting7Sites

Study ended1Sites

2024-04-01 - 2030-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-01-01 - 2030-12-31

Phase III

Active
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patients with generalized Myasthenia Gravis, followed by an open-label extension phase

  • Condition/Disease

    Generalized Myasthenia Gravis

  • Test Drug

    Remibrutinib

Participate Sites
5Sites

Recruiting5Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB